Skip to main content
. 2020 Aug 5;5(11):1255–1262. doi: 10.1001/jamacardio.2020.2981

Figure 3. Three-Year Kaplan-Meier Rates for the Primary End Point (a Composite of Cardiovascular [CV] Death, Myocardial Infarction [MI], or Stroke) by Atherosclerotic Cardiovascular Disease (ASCVD) Risk and High-Sensitivity Troponin I (hsTnI) Level.

Figure 3.

Patients in the guideline-derived very high-risk ASCVD group (overall 3-year event rate of 8.8%) were further risk stratified by hsTnI level. The 3-year event rates for CV death, MI, or stroke were 2.7% in patients with an hsTnI level less than 2 ng/L, 6.5% in patients with an hsTnI level of 2 to 6 ng/L, and 14.3% in patients with an hsTnI level exceeding 6 ng/L (P for trend <.001). Among patients in the lower-risk ASCVD group (overall 3-year event rate of 5.0%), hsTnI levels also provided a further gradient of risk. The 3-year event rates for CV death, MI, or stroke were 3.1% in patients with an hsTnI level less than 2 ng/L, 4.0% in patients with an hsTnI level of 2 to 6 ng/L, and 9.1% in patients with an hsTnI level exceeding 6 ng/L (P for trend <.001).